Gallen International Breast Cancer Conference reported a molecular subtype approach to guide the therapy of BC based on immunohistochemical markers: estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2)4. Here, ESR1 is linked to neoplasm.